Aquestive Therapeutics, Inc.
AQST
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Aquestive Therapeutics develops oral film-based drug delivery products using its proprietary PharmFilm technology. Its lead product Anaphylm (dibutepinephrine sublingual film) is an epinephrine prodrug for severe allergic reactions and anaphylaxis, currently seeking FDA approval after receiving a Complete Response Letter in January 2026 with NDA resubmission planned for Q3 2026. The company also develops a novel transbuccal insulin film and CNS pipeline candidates. Aquestive's novel drug delivery formulations require preclinical animal testing to establish bioavailability, pharmacokinetics, and toxicology profiles under FDA regulations. Its transbuccal insulin program published preclinical results demonstrating feasibility of oral film insulin delivery through animal absorption studies.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.